4/26
04:23 am
ipha
NK Cell Therapies Pipeline Report 2024: Insights on 80+ Companies and 100+ Pipeline Drugs, Including ALECSAT (CytoVac), NKTR-214/Bempegaldesleukin (Nektar Therapeutics), and Monalizumab (Innate Pharma) [Yahoo! Finance]
Neutral
Report
NK Cell Therapies Pipeline Report 2024: Insights on 80+ Companies and 100+ Pipeline Drugs, Including ALECSAT (CytoVac), NKTR-214/Bempegaldesleukin (Nektar Therapeutics), and Monalizumab (Innate Pharma) [Yahoo! Finance]
4/19
07:49 am
ipha
Natural Killer (NK) Cell Therapy Pipeline Research Report 2024: Comprehensive Insights About 100+ Companies and 185+ Pipeline Drugs [Yahoo! Finance]
Medium
Report
Natural Killer (NK) Cell Therapy Pipeline Research Report 2024: Comprehensive Insights About 100+ Companies and 185+ Pipeline Drugs [Yahoo! Finance]
4/15
10:19 am
ipha
Sezary Syndrome Pipeline Insights 2024, Featuring Major Players 4SC, Seagen, Merck Sharp & Dohme, Innate Pharma, Trillium Therapeutics and Secura Bio [Yahoo! Finance]
Low
Report
Sezary Syndrome Pipeline Insights 2024, Featuring Major Players 4SC, Seagen, Merck Sharp & Dohme, Innate Pharma, Trillium Therapeutics and Secura Bio [Yahoo! Finance]
4/15
01:12 am
ipha
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024 [Yahoo! Finance]
Low
Report
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024 [Yahoo! Finance]
4/15
01:00 am
ipha
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024
Low
Report
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024
4/15
01:00 am
ipha
Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients
Low
Report
Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients
4/11
08:06 am
ipha
Innate Pharma S.A. (NASDAQ: IPHA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.50 price target on the stock.
Low
Report
Innate Pharma S.A. (NASDAQ: IPHA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.50 price target on the stock.
4/10
01:21 pm
ipha
All You Need to Know About Innate Pharma (IPHA) Rating Upgrade to Buy [Yahoo! Finance]
Medium
Report
All You Need to Know About Innate Pharma (IPHA) Rating Upgrade to Buy [Yahoo! Finance]
4/10
01:06 am
ipha
Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate [Yahoo! Finance]
Medium
Report
Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate [Yahoo! Finance]
4/10
01:00 am
ipha
Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate
Medium
Report
Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate
4/9
01:00 am
ipha
Innate Pharma Announces Its Participation in Upcoming Investor Conference
Medium
Report
Innate Pharma Announces Its Participation in Upcoming Investor Conference
4/5
03:43 am
ipha
Innate Pharma Files Its 2023 Universal Registration Document (Document d'enregistrement Universel) and 2023 Annual Report on Form 20-F [Yahoo! Finance]
Low
Report
Innate Pharma Files Its 2023 Universal Registration Document (Document d'enregistrement Universel) and 2023 Annual Report on Form 20-F [Yahoo! Finance]
4/5
03:34 am
ipha
Innate Pharma Files Its 2023 Universal Registration Document (Document d’enregistrement Universel) and 2023 Annual Report on Form 20-F
Low
Report
Innate Pharma Files Its 2023 Universal Registration Document (Document d’enregistrement Universel) and 2023 Annual Report on Form 20-F
3/22
11:49 am
ipha
Innate Pharma S.A. (NASDAQ:IPHA) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Neutral
Report
Innate Pharma S.A. (NASDAQ:IPHA) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/22
08:07 am
ipha
Innate Pharma S.A. (NASDAQ: IPHA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.50 price target on the stock.
Low
Report
Innate Pharma S.A. (NASDAQ: IPHA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.50 price target on the stock.
3/21
02:10 am
ipha
Innate Pharma Reports Full Year 2023 Financial Results and Business Update [Yahoo! Finance]
Medium
Report
Innate Pharma Reports Full Year 2023 Financial Results and Business Update [Yahoo! Finance]
3/21
02:00 am
ipha
Innate Pharma Reports Full Year 2023 Financial Results and Business Update
Medium
Report
Innate Pharma Reports Full Year 2023 Financial Results and Business Update
3/19
02:00 am
ipha
Innate Pharma Announces Its Participation to Upcoming Investor Conference
Low
Report
Innate Pharma Announces Its Participation to Upcoming Investor Conference
3/14
02:00 am
ipha
Innate Pharma Announces Conference Call and Webcast for Full Year 2023 Financial Results
Low
Report
Innate Pharma Announces Conference Call and Webcast for Full Year 2023 Financial Results
3/6
01:15 am
ipha
Innate Pharma to Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data at AACR 2024 [Yahoo! Finance]
Medium
Report
Innate Pharma to Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data at AACR 2024 [Yahoo! Finance]
3/6
01:15 am
ipha
Innate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin's Lymphoma [Yahoo! Finance]
Medium
Report
Innate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin's Lymphoma [Yahoo! Finance]
3/6
01:00 am
ipha
Innate Pharma to Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data at AACR 2024
Medium
Report
Innate Pharma to Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data at AACR 2024
3/6
01:00 am
ipha
Innate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin’s Lymphoma
Medium
Report
Innate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin’s Lymphoma
2/21
01:11 am
ipha
Innate Pharma Announces Its Participation to Upcoming Investor Conference [Yahoo! Finance]
Low
Report
Innate Pharma Announces Its Participation to Upcoming Investor Conference [Yahoo! Finance]
2/21
01:00 am
ipha
Innate Pharma Announces Its Participation to Upcoming Investor Conference
Low
Report
Innate Pharma Announces Its Participation to Upcoming Investor Conference